Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04762862

QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy

"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB).

The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets.

Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations.

"

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Solid Tumor

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nice

Nice, 06000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ;
  • no standard or curative treatment available;
  • non-opposition of the patient collected.

Exclusion criteria

  • multiple cancer patient;
  • ECOG Scale of Performance Status (PS) ≥2

Treatment and study plan

Primary outcomes

  1. Number of targeted molecular alterations

    Time frame: at day 0

    Number of targeted molecular alterations

Secondary outcomes

  1. Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)

    Time frame: at day 0

    Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Collaborators

  • Centre Antoine Lacassagne

Registry information

Acronym: QUANTACT

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Feb 21, 2021
Registry last updated
Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.